Armen G. Aprikian

Canadian Journal of Urology, Vol.9, Suppl.1, pp. 18-20, 2002

Abstract Clinical outcomes in patients with localized prostate cancers are heterogeneous. In recent years, analyses of large datasets from multiple centres have yielded a better understanding of how to measure risk in localized prostate cancer. Regardless of whether patients are treated with prostatectomy, radiotherapy, brachytherapy, or expectant management, three factors appear correlated with clinical outcome: biopsy Gleason score, clinical T stage, and serum prostate-specific antigen (PSA). Partin Tables, derived from these parameters and recently updated and refined, may be used to estimate the risk of metastasis and to assess certain aspects of surgical management in clinically… More >

Yves Fradet

Canadian Journal of Urology, Vol.9, Suppl.1, pp. 8-13, 2002

Abstract Many methods exist to define high-risk prostate cancer. These include clinical stage, serum PSA, and pathological features such as Gleason score and the number of positive biopsies. Partin tables are widely used to stratify patients according to risk of adverse pathological features at surgery, and to identify those more likely to remain free of recurrent disease following surgery. The priority in most patients with localized prostate cancer remains the selection of a treatment that will provide them with the best chance for cure. While treatment-related morbidity is an important issue, we believe that side effects… More >

Laurence H. Klotz, Richard Choo, Gerard Morton, Cyril Danjoux

Canadian Journal of Urology, Vol.9, Suppl.1, pp. 2-7, 2002

Abstract The optimal management of clinically localized prostate cancer remains unresolved. Management options range from a conservative approach to definitive treatment. While evidence suggests that expectant management yields similar 10-year survival rates and quality-adjusted life years compared to definitive treatment, this approach alone will deprive some patients with potentially curable disease of the opportunity for curative therapy. Effective management of localized prostate cancer requires differentiation between patients with biologically aggressive disease, in whom curative therapy is strongly warranted, and those with indolent malignancy, in whom conservative management would be equally efficacious. A comparison of surveillance studies… More >

Darrel E. Drachenberg¹, David G. Bell²

Canadian Journal of Urology, Vol.9, No.4, pp. 1602-1606, 2002

Abstract Background: The treatment of localized prostate cancer has increased over the past decade in large part due to enhanced screening efforts with prostate specific antigen (PSA) and has resulted in a dramatic increase in the number of radical retropubic prostatectomies being performed in recent years. It is estimated that between 5% and 10% of men who are candidates for radical surgical treatment for localized prostate cancer will have concomitant inguinal hernia. Given the well described complications of untreated inguinal hernias we propose that simultaneous repair be undertaken along with radical retropubic prostatectomy for preoperatively defined hernias More >

Marc David¹, Luis Souhami¹, Armen Aprikian²

Canadian Journal of Urology, Vol.9, No.4, pp. 1599-1601, 2002

Abstract A case of post renal acute renal failure secondary to radiation therapy for prostate cancer is described. Severe bladder inflammatory reaction, leading to bilateral ureteric obstruction, occurred after a moderate dose of radiotherapy (6400 cGy in 35 fractions). At a follow-up time of 8 years, the patient has fully recovered and remains disease-free. To our knowledge, this complication has never been described previously. Given the thrust in prostate cancer treatment toward dose escalation this complication could become more frequent. More >

Fred Saad, Robert Sabbagh, Michael McCormack, François Peloquin

Canadian Journal of Urology, Vol.9, No.4, pp. 1592-1594, 2002

Abstract Purpose: To compare patient reported pain during TRUS guided biopsies using intrarectal lidocaine gel versus lubricating gel.
Materials and methods: From May 2000 to May 2001, 360 men undergoing transrectal prostate biopsy were enrolled in this study. Patients were randomized into two groups. In group 1, 180 patients received 10 cc of 2% intrarectal lidocaine gel (Xylocaine® 2% jelly, Astra Pharma Inc.) 5 to 10 minutes before the procedure and in group 2, 180 patients received 10 cc of lubricating gel. No other sedation or analgesia was given. Pain level immediately after the last biopsy was assessed More >

Tom Pickles¹, Andy Coldman², Norm Phillips³

Canadian Journal of Urology, Vol.9, No.3, pp. 1551-1557, 2002

Abstract Objective: To evaluate changes of prostate cancer incidence, referrals, stage, treatment and outcomes delivered in British Columbia since the 1980's.
Materials and methods: Examination of the BC Provincial Tumour Registry, BC Cancer Agency (BCCA) and BC Medical Services Plan databases.
Results: The number of incident cases increased linearly from 1980 through 1990. Between 1991 and 1995 a harvesting effect was seen due to unofficial PSA screening, balanced by a post-harvest effect between 1995 and 1998. Since 1999 the incidence has resumed the linear trend extrapolated from the 1980's. The age-standardised incidence rate has recently risen in younger (<65yrs)… More >

Yves Fradet

Canadian Journal of Urology, Vol.9, No.3, pp. 1544-1550, 2002

Abstract Superficial bladder tumors are by far the most common form of bladder cancer managed by practicing urologists. Indeed up to 75% of initial tumors fall in this category and because of the high recurrence rate, superficial tumors represent over 90% of tumor events being treated. New diagnostic methods have been developed to improve the sensitivity of tumor detection of both cystoscopy and urinary cytology. Risk stratification of patients based on simple clinical parameters provides new opportunities for adapting monitoring strategies as well as providing a rationale for the use of intravesical chemotherapy and immunotherapy. Finally, More >

Ö. L. Özdal¹, Y. K. Yakupoglu¹, A. Çiçek¹, Ö. Erdem², L. Memis², A. Memis¹

Canadian Journal of Urology, Vol.9, No.2, pp. 1498-1499, 2002

Abstract We report a 55 year old man complaining of painless left testicular swelling that developed over 2 months. The imaging studies revealed an epididymal mass separate from the testicle. The patient underwent left radical orchiectomy. The histopathological examination of the orchiectomy specimen revealed poorly differentiated signet cell metastatic adenocarcinoma. More >

Iain McAuley¹, Gary Steinhoff¹, Michael McNeely², Paul Blood³

Canadian Journal of Urology, Vol.9, No.2, pp. 1496-1497, 2002

Abstract A man with a prostate specific antigen (PSA) of 6.1 ng/mL, a clinical stage T2b prostate nodule and biopsies that showed Gleason sum 6 adenocarcinoma of the prostate underwent a radical prostatectomy. The final pathology showed organ-confined disease. His postoperative PSA remained elevated at 4.0 ng/mL. The PSA was repeated several times and was in the same range. It was re-evaluated at another lab facility and was unmeasurable ( <0.02 ng/mL). He has an antibody that cross-reacts with an assay reagent causing this false reading. The most likely antibody is one against mouse immunoglobulin G More >